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Abstract: Sequence determination of complete or coding-complete genomes of viruses is 
becoming  common  practice  for  supporting  the  work  of  epidemiologists,  ecologists, 
virologists,  and  taxonomists.  Sequencing  duration  and  costs  are  rapidly  decreasing, 
sequencing  hardware  is  under  modification  for  use  by  non-experts,  and  software  is 
constantly  being  improved  to  simplify  sequence  data  management  and  analysis.  
Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including 
characterization  of  the  evolution  of  individual  virus  populations  in  single  patients over 
time. The increasing accumulation of sequencing data creates a management problem for 
the curators of commonly used sequence databases and an entry retrieval problem for end 
users. Therefore, utilizing the data to their fullest potential will require setting nomenclature 
and annotation standards for virus isolates and associated genomic sequences. The National 
Center  for  Biotechnology  Information’s  (NCBI’s)  RefSeq  is  a  non-redundant,  curated 
database for reference (or type) nucleotide sequence records that supplies source data to 
numerous other databases. Building on recently proposed templates for filovirus variant 
naming [<virus name> (<strain>)/<isolation host-suffix>/<country of sampling>/<year of 
sampling>/<genetic  variant  designation>-<isolate  designation>],  we  report  consensus 
decisions  from  a  majority  of  past  and  currently  active  filovirus  experts  on  the  eight 
filovirus type variants and isolates to be represented in RefSeq, their final designations, and 
their associated sequences. 
Keywords: Bundibugyo virus; cDNA clone; cuevavirus; Ebola; Ebola virus; ebolavirus; 
filovirid;  Filoviridae;  filovirus;  genome  annotation;  ICTV;  International  Committee  on 
Taxonomy  of  Viruses;  Lloviu  virus;  Marburg  virus;  marburgvirus;  mononegavirad; 
Mononegavirales;  mononegavirus;  Ravn  virus;  RefSeq;  Reston  virus;  reverse  genetics; 
Sudan virus; Taï Forest virus; virus classification; virus isolate; virus nomenclature; virus 
strain; virus taxonomy; virus variant 
 
1. Introduction 
The National Center for Biotechnology Information (NCBI) RefSeq project was initiated to create a 
nonredundant  and  curated  set  of  genomic,  transcript,  and  protein  sequence  records  [1].  Genomic 
RefSeq records provide a reference nucleotide sequence wherein individual protein coding regions and 
other sequence features are annotated, using the best available experimental data as a guide. Akin to 
the labeling of reference specimens as type specimens in other taxonomic schemes, RefSeq reference 
sequences can be considered type sequences for type viruses.  Viruses 2014, 6  3667 
 
 
In the case of virological RefSeq records, each viral species was initially represented by only one 
genome  sequence  record,  and  all  other  genome  records  for  members  of  the  same  species,  or  for 
different strains, variants, and isolates of the same member of this species were linked to this record as 
“genome neighbors” [2]. The rationale behind choosing a particular virus isolate sequence as reference 
sequence  is  unclear  in  most  cases  and  has  almost  never  been  published.  Annotation  of  individual 
RefSeq entries was performed using PubMed-indexed experimental data through NCBI inhouse and 
individual  expert  curation,  since  subspecialty-wide  committees  or  expert  groups  had  not  been 
established.  
The process of curating genome sequence data must now be fundamentally reformed, since the 
number of sequenced viral genomes has increased exponentially over the past decade [3]. Little to no 
experimental data are available for most new virus genomes, and annotation is often computationally 
transferred from related genomes or predicted de novo [4]. Moreover, the utility of reference genomes 
has  expanded  to  include  use  in  sequence  assembly  and  pathogen  detection  pipelines  [5–9].  With  
these  changes,  the  data  model  has  adapted,  and  multiple  RefSeq  records  can  now  be  maintained  
for several members of a particular virus species. This approach offers representation of the extant 
sequence  diversity  (or  genotypes)  within  a  particular  species.  Also,  the  approach  provides  a 
mechanism to maintain well annotated records from experimentally important laboratory isolates and 
from less studied isolates from the wild. 
2. Current Filovirus RefSeq Entries 
The  mononegaviral  family  Filoviridae  includes  three  genera,  Cuevavirus,  Ebolavirus,  and 
Marburgvirus.  Eight  distinct  filoviruses  are  recognized  as  members  of  a  total  of  seven  species 
distributed among these three genera (Table 1) [10–14].  Viruses 2014, 6  3668 
 
 
Table 1. Summary of the current filovirus taxonomy endorsed by the 2012-2014 ICTV Fi-
loviridae Study Group and accepted by the ICTV. 
Current Taxonomy and Nomenclature (Ninth ICTV Report and Updates) 
Order Mononegavirales 
   Family Filoviridae 
      Genus Marburgvirus 
         Species Marburg marburgvirus 
            Virus 1: Marburg virus (MARV) 
            Virus 2: Ravn virus (RAVV) 
      Genus Ebolavirus 
         Species Taï Forest ebolavirus 
            Virus: Taï Forest virus (TAFV) 
         Species Reston ebolavirus 
            Virus: Reston virus (RESTV) 
         Species Sudan ebolavirus 
            Virus: Sudan virus (SUDV) 
         Species Zaire ebolavirus 
            Virus: Ebola virus (EBOV) 
         Species Bundibugyo ebolavirus 
            Virus: Bundibugyo virus (BDBV) 
      Genus Cuevavirus 
         Species Lloviu cuevavirus 
                 Virus: Lloviu virus (LLOV) 
These  eight  viruses  are  differentiated  from  each  other  by  biological  characteristics  [12]  and 
genomic sequence divergence  [11,12,15,16]. This divergence is determined  based on sequences of 
well-characterized variants of root viruses (from here on called type variants of type viruses) for each 
taxon [12]. These sequences, therefore, become de facto type sequences. Using type sequences allows 
algorithmic representation of filovirus relationships and newly isolated filoviruses can theoretically be 
automatically pre-assigned to existing or novel taxa (Figure 1). Temporary type filovirus variants were 
established  by the 2010–2011 ICTV Filoviridae Study Group [12]. These temporary type  variants 
were largely consistent with those chosen for RefSeq (Table 2) by  the NCBI, which automatically 
chose the first sequence available for a new virus.  
 
Table 2. Temporary filovirus type viruses and type variants chosen by the 2010-2011 ICTV Filoviridae Study Group [27], and filovirus type 
sequences available from RefSeq. 
Filovirus Species 
Type Virus of Species  
(Virus Abbreviation) 
Type Variant and Isolate  
of Type Virus of Species 
Type Sequence of Type Variant  
of Type Virus of Species (RefSeq) 
Bundibugyo ebolavirus 
 
Lloviu cuevavirus 
Marburg marburgvirus 
Reston ebolavirus 
Sudan ebolavirus 
Taï Forest ebolavirus 
Zaire ebolavirus 
Bundibugyo virus 
(BDBV) 
Lloviu virus (LLOV) 
Marburg virus (MARV) 
Reston virus (RESTV) 
Sudan virus (SUDV) 
Taï Forest virus (TAFV) 
Ebola virus (EBOV) 
Unnamed variant represented by isolate “811250”
1 
 
Unnamed variant represented by isolate “MS-Liver-86/2003”
2 
Unnamed variant represented by isolate “Musoke” 
Unnamed variant represented by isolate “Pennsylvania” 
Unnamed variant represented by isolate “Boniface” [sic]
3 
Unnamed variant represented by isolate “Côte d’Ivoire”
4 
Unnamed variant represented by isolate “Mayinga” 
NC_014373 
 
NC_016144 
NC_001608 
NC_004161 
None 
NC_014372 
NC_002549 
1 Isolate “811250” is/was not explicitly mentioned in [12] or RefSeq entry NC_014373 at the time of writing, but could be deduced from [17]; 
2 The RefSeq isolate name 
“MS-Liver-86/2003” is mentioned only as “sample 86” in [18]. Note that LLOV has not been isolated in culture yet. “Isolate” here refers to the theoretical isolate, the cod-
ing sequences of which would correspond to this RefSeq sequence; 
3 ”Boneface” is often misspelled “Boniface” in the literature, including in [12]. A review of original 
sample records at CDC clearly identified the correct name as “Boneface” (Stuart T. Nichol and Pierre E. Rollin, personal communication). RefSeq does not contain a 
“Boneface” entry but at the time of writing instead listed SUDV variant “Gulu” without an isolate reference (NC_006432); 
4RefSeq entry NC_014372 did not contain an 
isolate name at the time of writing. Viruses 2014, 6  3670 
 
 
These variants and sequences therefore needed to be re-evaluated by filovirus experts. To achieve 
uniformity and consistency, the current RefSeq entries  have to be relabeled to conform to current 
ICTV taxonomy. In addition, type filovirus variant designations have to be chosen and the individual 
isolate names  have to be adjusted to the  filovirus strain/variant/isolate schemes that were recently 
established [19]. 
 
 
 
Figure 1. Genome-based classification of novel filoviruses or filovirus genomic sequences. 
Viruses are classified in the family Filoviridae (order Mononegavirales) based on a list of 
biophysical criteria, genomic organization, the type of disease the viruses cause  in pri-
mates, geographic distribution, and morphology of their virions (outlined in [11,12]). Once 
a novel virus isolate clearly belongs to this family, genomic sequence comparison can help 
classification into lower taxa. Novel isolates are classified by comparing the genomic se-
quence of the new isolate first to the genomic sequences to the type viruses of the ICTV-
accepted genera, and then to viruses of the ICTV-accepted species. Using taxon-specific Viruses 2014, 6  3671 
 
 
genomic sequence divergence cut-offs, the novel isolate can then be automatically classi-
fied into existing taxa, unless they require the establishment of novel taxa through existing 
ICTV mechanisms. 
3. RefSeq Entry Reevaluation 
The “gold standard” filovirus type RefSeq entry should be selected on the basis of experimental 
importance  and  accessibility  and  represent  a  repository  of  functional  information  about  a  
particular  filovirus.  It  is  of  crucial  importance  that  any  functional  annotation  of  a  RefSeq  entry  
(e.g.,  functions  of  particular  genome  parts  or  of  genome-encoded  proteins),  is  linked  to  the  actual 
sequence associated with these experiments. The RefSeq entry should contain the most characterized 
virus/variant/isolate/sequence, independent of whether this virus, variant, or isolate was the first one 
discovered or the most widely used experimentally. Importantly, decisions on RefSeq entries do not 
entail a mandate that future experiments should necessarily be performed with the viruses associated 
with  these  entries.  However,  direct  comparisons  with  RefSeq-associated  viruses  are  highly 
recommended to further increase the detail associated with the RefSeq entries. These entries should be 
updated,  and,  if  necessary,  corrected  on  a  continuous  basis  by  a  filovirus  RefSeq  subcommittee 
comprised of filovirus experts, whose composition is currently under consideration.  
The authors of this article confirmed or replaced the current taxonomic type virus variants and 
isolates and the current filovirus RefSeq entries based on the availability of scientific  information 
characterizing a particular virus. If scientific information is scarce for all members belonging to an 
entire taxon, other criteria such as availability, passaging history, or medical importance were used in 
decision  making.  Decisions  were  reached  by  consensus  or  simple  majority  voting,  with  the 
understanding that all authors will apply the final decisions reached by the entire group and enforce 
them in their functions as authors, peer-reviewers, and/or editors. 
3.1. Cuevavirus RefSeq Entries 
Only one cuevavirus, Lloviu virus (LLOV), has been described [18]. At the time of writing, LLOV 
had not been isolated in culture, and the sequence diversity of LLOV had only been defined in a single 
study using deep sequencing techniques on samples from deceased Schreibers’s long-fingered bats 
(Miniopterus  schreibersii)  [18].  Only  one  additional  study  has  been  published  on  this  virus, 
characterizing  molecular-biological  characteristics  of  the  LLOV  glycoprotein  [20].  The  coding-
complete  genome  of  one  LLOV  has  been  determined  (Genbank  #JF828358),  which  therefore 
automatically  became  the  current  RefSeq  sequence  (#NC_016144)  (see  [21]  for  sequencing 
nomenclature  used  in  this  article).  In  the  absence  of  additional  deposited  LLOV  sequences  and 
characterization data, this RefSeq entry should therefore be upheld but be considered temporary until a 
complete genome, including all non-coding sequences, is determined. 
In  line  with  filovirus  strain/variant/isolate  definitions  outlined  previously  [19],  we  propose  
the  variant  designation  “Asturias”  (after  the  Principality  of  Asturias  in  Spain,  where  Cueva  del  
Lloviu  is  located in which LLOV was discovered [18]) and the “isolate” name “Bat86” (instead of  
“MS-Liver-86/2003”) for this virus: Viruses 2014, 6  3672 
 
 
Full name:     Lloviu virus M.schreibersii-wt/ESP/2003/Asturias-Bat86 
Shortened name:     LLOV/M.sch/ESP/03/Ast-Bat86 
Abbreviated name:    LLOV/Ast-Bat86 
Accordingly,  in  RefSeq  #NC_016144  the  definition  line  “Lloviu  virus,  complete  genome”  was 
changed  to  “Lloviu  cuevavirus  isolate  Lloviu  virus  M.schreibersii-wt/ESP/2003/Asturias-Bat86, 
[coding-]complete genome.” The RefSeq <strain> field was cleared; and the RefSeq <isolate> field 
was filled with “Lloviu virus M.schreibersii-wt/ESP/2003/Asturias-Bat86.” The same changes should be 
applied  to  GenBank  #JF828358.  [Note  here  and  below  that  the  International  Nucleotide  Sequence 
Database Collaboration (INSDC) standard currently does not offer options other than “complete” or 
“partial,” and, in particular, does not provide a possibility for the designation “coding-complete.” Also 
note here and below that neither RefSeq nor GenBank currently can handle italics or extended Latin 
characters,  which  is  why  the  species  names  are  not  italicized  in  the  entry’s  definition  line  and 
<organism> fields and why letters with diacritics revert to their basic Latin letter counterpart]. 
3.2. Ebolavirus RefSeq Entries 
The genus Ebolavirus includes five species, each of which is represented by one virus. 
3.2.1. Bundibugyo Virus 
Bundibugyo  virus (BDBV)  is the second  least characterized ebolavirus. Although at least eight 
isolates of this virus are available [17,22], all experiments reported to date have been performed with 
one particular isolate, “811250” (often wrongly referred to as “200706291”). The complete sequence 
of this isolate is the one found in the current RefSeq entry (NC_014373). This isolate, obtained after 
two  passages  of  clinical  material  in  Vero  E6  cells,  came  from  a  male  patient  who  died  in  2007  
in Uganda [17]. We propose the variant designation “Butalya” (after Butalya Parish, Kikyo Subcounty 
in Uganda’s Bundibugyo district where BDBV was discovered) and the isolate name “811250” for  
this virus: 
Full name:    Bundibugyo virus H.sapiens-tc/UGA/2007/Butalya-811250 
Shortened name:   BDBV/H.sap/UGA/07/But-811250 
Abbreviated name:  BDBV/But-811250 
Accordingly,  in  RefSeq  #NC_014373,  the  definition  line  “Bundibugyo  ebolavirus,  
complete  genome”  was  changed  to  “Bundibugyo  ebolavirus  isolate  Bundibugyo  virus  
H.sapiens-tc/UGA/2007/Butalya-811250, complete genome.” The RefSeq <isolate>  field was  filled 
with  “Bundibugyo  virus  H.sapiens-tc/UGA/2007/Butalya-811250.”  The  same  changes  should  be 
applied to GenBank #FJ217161. Viruses 2014, 6  3673 
 
 
3.2.2. Ebola Virus 
Ebola virus (EBOV) is the most thoroughly characterized ebolavirus. Dozens of EBOV isolates are 
available,  but  the  vast  majority  of  published  experiments  have  been  performed  with  isolates 
“Mayinga” and “Kikwit” (reviewed in [23]). The “Mayinga” isolate, the first EBOV isolate obtained in 
1976,  has  been  used  extensively  for  molecular-biological  characterizations.  The  “Kikwit”  variant, 
obtained  during  an  Ebola  virus  disease  outbreak  in  1995,  has  been  used  almost  exclusively  for 
pathogenesis  studies  in  nonhuman  primates  in  the  US  (the  “Mayinga”  isolate  is  used  almost 
everywhere else) [23]. All available EBOV cDNA clone systems are based on the “Mayinga” isolate 
(see [24]). The only available  mouse- and guinea pig-adapted EBOV strains are derived  from the 
“Mayinga” isolate (see [25]), and all available EBOV protein crystal structures are derived from the 
“Mayinga” isolate [26–34]. The “Mayinga” isolate was therefore chosen as the prototype EBOV for 
RefSeq (#NC_002549), which lists a complete genome obtained after 3–4 passages in Vero E6 cells. 
We uphold this decision and propose the variant designation “Yambuku” (after the village in which 
EBOV first emerged [35,36]) and retain the isolate designation “Mayinga” (the last name of a nurse 
who succumbed to infection [36]) for this virus: 
Full name:    Ebola virus H.sapiens-tc/COD/1976/Yambuku-Mayinga 
Shortened name:   EBOV/H.sap/COD/76/Yam-May 
Abbreviated name:  EBOV/Yam-May 
Accordingly, in RefSeq #NC_002549 the definition line “Zaire ebolavirus, complete genome” was 
changed  to  “Zaire  ebolavirus  isolate  Ebola  virus  H.sapiens-tc/COD/1976/Yambuku-Mayinga, 
complete genome.” The RefSeq <strain” field was cleared; the RefSeq <isolate> field was filled with 
“Ebola virus H.sapiens-tc/COD/1976/Yambuku-Mayinga;” and the <organism> field was corrected to 
“Zaire ebolavirus.” The same changes should be applied to GenBank #AF086833. 
3.2.3. Reston Virus 
Reston virus (RESTV) has caused multiple epizootics among captive macaques (1989-1990, 1992, 
1996) and domestic pigs in 2008 (reviewed in [37]). At least 10 isolates were obtained during all these 
outbreaks, and eight complete or coding-complete genomic sequences have been deposited. However, 
the vast majority of RESTV experiments,  in particular  those regarding  molecular characterization, 
have  been  performed  with  “Pennsylvania”  (reviewed  in  [23]).  “Pennsylvania”  is  the  only  RESTV 
variant for which there is a reverse genetics system [38]. In addition, “Pennsylvania” sequences served 
as the basis for the available RESTV protein crystal structures [39–43]. “Pennsylvania” (NC_004161) 
was chosen for the current RESTV RefSeq entry, which we propose to maintain. We propose the 
variant  designation  “Philippines89”  (a  reference  to the  time  and  place  from  which  this  virus  was 
exported to the US in 1989) and the isolate name “Pennsylvania” for this virus: 
Full name:    Reston virus M.fascicularis-tc/USA/1989/Philippines89-Pennsylvania 
Shortened name:   RESTV/M.fas/USA/89/Phi89-Pen 
Abbreviated name:  RESTV/Phi89-Pen Viruses 2014, 6  3674 
 
 
Accordingly, in RefSeq #NC_004161, the definition line “Reston ebolavirus, complete genome” 
was  changed  to  “Reston  ebolavirus  isolate  Reston  virus  M.fascicularis-tc/USA/1989/Philippines89-
Pennsylvania, complete genome.” The RefSeq <strain> field was cleared; and the RefSeq <isolate> 
field was filled with “Reston virus M.fascicularis-tc/USA/1989/Philippines89-Pennsylvania”. The same 
changes should be applied to GenBank #AF522874. 
3.2.4. Sudan Virus 
Sudan virus (SUDV) is the second-best characterized ebolavirus. Approximately 15 SUDV isolates 
have been described, but very few experiments have been performed with any of these isolates. Early 
experiments focused on isolate “Boneface” (often misspelled “Boniface”). Recently variant “Gulu” 
isolate  “808892”  has  become  a  more  popular  choice,  and  data  from  experiments  with  this  virus 
continue  to  accumulate  (reviewed  in  [23]).  Crystal  structures  for  GP1,2  were  determined  for  both 
viruses  [33,42,44,45].  However,  the  passaging  history  of  the  “Boneface”  isolate  has  not  been 
thoroughly documented and  includes passaging  in guinea pigs and culturing  in  various cell types.  
The “Gulu-808892” isolate, on the other hand, is completely sequenced and is the current virus of 
choice for nonhuman primate experiments in the US. While the “Boneface” isolate was chosen by the 
2010-2011 ICTV Filoviridae Study Group as the type SUDV [12], “Gulu-808892” isolate was chosen 
as the prototype SUDV for RefSeq (#NC_006432). We propose to support the RefSeq decision and to 
change the SUDV type virus variant to “Gulu.” As several “Gulu” isolates are available, we propose 
the variant designation “Gulu” for the virus variant that caused the disease outbreak that started in 
Gulu District, Uganda, in 2000, and the isolate designation “808892” for the RefSeq entry of this 
particular virus. (“808892” was obtained after three Vero E6 cell passages of clinical material coming 
from an infected male who died): 
Full name:    Sudan virus H.sapiens-tc/UGA/2000/Gulu-808892 
Shortened name:   SUDV/H.sap/UGA/00/Gul-808892 
Abbreviated name:  SUDV/Gul-808892 
Accordingly,  in  RefSeq #NC_006432, the definition  line  “Sudan ebolavirus, complete genome” 
was  changed  to  “Sudan  ebolavirus  isolate  Sudan  virus  H.sapiens-tc/UGA/2000/Gulu-808892, 
complete genome.” The RefSeq <strain> field was cleared; and the RefSeq <isolate> field was filled 
with  “Sudan  virus  H.sapiens-tc/UGA/2000/Gulu-808892.”  The  same  changes  should  be  applied  to 
GenBank #AY729654. 
3.2.5. Taï Forest Virus 
Taï Forest virus (TAFV) is the least characterized ebolavirus. Only one isolate (“807212” = “CI”) 
was obtained  from a  female survivor  [46] after seven passages  in Vero E6 cells, and the coding-
complete genome of this isolate is the only genomic TAFV sequence available [17]. Therefore, this 
sequence  automatically  became  the  current  RefSeq  sequence  (#NC_014372).  In  the  absence  of 
additional deposited TAFV sequences and characterization data, this RefSeq entry should therefore be 
upheld but be considered temporary. Viruses 2014, 6  3675 
 
 
We propose the variant designation “Pauléoula” (after the village of Pauléoula, Guiglo Department 
in Moyen-Cavally Region, Côte d’Ivoire, where TAFV was first found [46]) and the isolate name “CI” 
(for “Côte d’Ivoire”) for this virus: 
Full name:    Taï Forest virus H.sapiens-tc/CIV/1994/Pauléoula-CI 
Shortened name:   TAFV/H.sap/CIV/94/Pau-CI 
Abbreviated name:  TAFV/Pau-CI 
Accordingly,  in  RefSeq  #  NC_014372,  the  definition  line  “Tai  Forest  ebolavirus,  
complete  genome”  was  changed  to  “Taï  Forest  ebolavirus  isolate  Taï  Forest  virus  
H.sapiens-tc/CIV/1994/Pauléoula-CI, [coding-]complete genome,” and the RefSeq <isolate> field was 
filled  with  “Taï  Forest  virus  H.sapiens-tc/CIV/1994/Pauléoula-CI.”  The  same  changes  should  be 
applied to GenBank #FJ217162. 
3.3. Marburgvirus RefSeq Entries 
The genus Marburgvirus includes a single species, which is represented by two divergent viruses. 
3.3.1. Marburg Virus 
Marburg  virus  (MARV)  is  the  most  thoroughly  characterized  marburgvirus.  Some  70  MARV 
isolates are available, but the majority of published experiments have been  performed with isolate 
“Musoke” (reviewed in [23]). However, experiments not characterizing MARV but rather the disease 
it causes are increasingly performed with an “Angola” isolate in the US and continue to be performed 
with “Popp” or “Voege” isolates in Russia. The only available MARV cDNA clone systems are based 
on the “Musoke” isolate (see [24]) and on a nonhuman (bat) isolate [47]. The “Musoke” isolate has 
therefore been chosen as the prototype MARV for RefSeq (#NC_001608). We uphold this decision 
and propose the variant designation “Mt. Elgon” (after Mount Elgon, Kenya, where this variant is 
thought to have originated [48]) and the isolate designation “Musoke” (after a Nairobi doctor who got 
infected [49]) with this virus): 
Full name:    Marburg virus H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke 
Shortened name:   MARV/Hsap/KEN/80/MtE-Mus 
Abbreviated name:  MARV/MtE-Mus 
Accordingly,  in  RefSeq  #NC_001608,  the  definition  line  “Marburg  marburgvirus,  complete 
genome” was changed to “Marburg marburgvirus isolate Marburg virus H.sapiens-tc/KEN/1980/Mt. 
Elgon-Musoke, complete genome.” The RefSeq <strain” field was cleared, and the RefSeq <isolate> 
field was filled with “Marburg virus H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke.” The same changes 
should be applied to GenBank #DQ217792. 
3.3.2. Ravn Virus 
Ravn virus (RAVV) is a largely uncharacterized marburgvirus that belongs to the same species as 
MARV. At least three human (“Ravn” = “810040,” “09DCR,” ”02Uga”) and four Egyptian rousette 
isolates  (“44Bat,”  “188Bat,”  “982Bat,”  “1304  Bat”)  have  been  obtained.  Virtually  all  RAVV Viruses 2014, 6  3676 
 
 
characterization experiments have been performed with “Ravn” = “810040,” which was obtained after 
at  least  two  passages  in  SW-13  cells  and  four  passages  in  Vero  E6  cells.  Since  RAVV  is  a 
phylogenetically distinct marburgvirus, we created a RefSeq entry for the “Ravn” isolate, for which we 
propose the variant designation “Kitum Cave” (after Kenya’s Kitum Cave on Mount Elgon where 
RAVV first emerged) and the isolate designation “810040”: 
Full name:    Ravn virus H.sapiens-tc/KEN/1987/Kitum Cave-810040 
Shortened name:  RAVV/H.sap/KEN/87/KiC-810040 
Abbreviated name:  RAVV/KiC-810040 
Accordingly, the RefSeq entry was created with the definition line “Marburg marburgvirus isolate 
Ravn  virus  H.sapiens-tc/KEN/1987/Kitum  Cave-810040,  [coding-]complete  genome.”  The  RefSeq 
<isolate>  field  contains  “Ravn  virus  H.sapiens-tc/KEN/1987/Kitum  Cave-810040.”  The  deposited 
sequence (NC_024781) is identical with GenBank #DQ447649, which should be updated accordingly. 
 
A summary of the proposed designations and RefSeq accession numbers can be found in Table 3.Viruses 2014, 6  3677 
 
 
 
Table 3. Final filovirus type viruses/variants/isolates/sequences. 
Filovirus Species 
Type Virus of Species  
(Virus Abbreviation) 
Type Variant and Isolate  
of Type Virus of Species 
Type Sequence of  
Type Variant of 
Type  
Virus of Species 
(RefSeq) 
Bundibugyo ebolavirus 
Lloviu cuevavirus 
Marburg marburgvirus 
Reston ebolavirus 
Sudan ebolavirus 
Taï Forest ebolavirus 
Zaire ebolavirus 
Bundibugyo virus (BDBV) 
Lloviu virus (LLOV) 
Marburg virus (MARV) 
Reston virus (RESTV) 
Sudan virus (SUDV) 
Taï Forest virus (TAFV) 
Ebola virus (EBOV) 
Bundibugyo virus H.sapiens-tc/UGA/2007/Butalya-811250
 
Lloviu virus M.schreibersii-wt/ESP/2003/Asturias-Bat86
1 
Marburg virus H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke 
Reston virus M.fascicularis-tc/USA/1989/Philippines89-Pennsylvania 
Sudan virus H.sapiens-tc/UGA/2000/Gulu-808892 
Taï Forest virus H.sapiens-tc/CIV/1994/Pauléoula-CI
 
Ebola virus H.sapiens-tc/COD/1976/Yambuku-Mayinga 
NC_014373 
NC_016144 
NC_001608 
NC_004161 
NC_006432 
NC_014372 
NC_002549 
1 Note that LLOV has not been isolated in culture yet. “Isolate” here refers to the theoretical isolate, the coding sequences of which would cor-
respond to this RefSeq sequence.Viruses 2014, 6  3678 
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